TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35059291

Group type: EXPERIMENTAL
Intervention: Nonsurgical traditional Korean medical treatment
Number of subjects: 65
Study: 35060395

Group type: EXPERIMENTAL
Intervention: Citizen responders activated by a smartphone application during evening hours (4:00-11:59 pm)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Citizen responders activated by a smartphone application during daytime hours (07:00 am-03:59 pm)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Citizen responders activated by a smartphone application during nighttime hours (12:00-06:59 am)
Number of subjects: 438
Study: 35060479

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccination
Number of subjects: 0
Study: 35060784

Group type: EXPERIMENTAL
Intervention: @ctivehip telerehabilitation program (12 weeks duration)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Traditional care and rehabilitation provided by the Andalusian Public Health Care System (Control)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: @ctivehip telerehabilitation program
Number of subjects: 71
Study: 35060907

Group type: EXPERIMENTAL
Intervention: InTSHA intervention (mobile phone-based intervention using WhatsApp, 10 modules conducted weekly)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: InTSHA intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 80
Study: 35060914

Group type: EXPERIMENTAL
Intervention: Microbial Ecosystem Therapeutic-2 (MET-2), 3 capsules per day for 8 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Microbial Ecosystem Therapeutic-2 (MET-2)
Number of subjects: 12
Study: 35061093

Group type: EXPERIMENTAL
Intervention: Late-onset COVID-19 infection in neonates
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Clinical findings associated with severe disease
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Laboratory findings
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Prothrombin time above 14 seconds
Number of subjects: 176
Study: 35061112

Group type: EXPERIMENTAL
Intervention: ePRO with triggered alerts as an add-on to standard care
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 138
Study: 35061234

Group type: EXPERIMENTAL
Intervention: Abrocitinib
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Abrocitinib coadministration with rifampin
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Abrocitinib coadministration with fluconazole and fluvoxamine, inflammatory skin conditions (psoriasis/AD), and hepatic impairment
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Asian participants
Number of subjects: 995
Study: 35061249

Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 1190
Study: 35061509

Group type: EXPERIMENTAL
Intervention: Severe global fatigue at T2 (score ≥ 40/100, EORTC QLQ-C30)
Number of subjects: 5640

Group type: EXPERIMENTAL
Intervention: Severe pretreatment fatigue
Number of subjects: 5640
Study: 35061577

Group type: EXPERIMENTAL
Intervention: Invasive ventilation
Number of subjects: 0
Study: 35061769

Group type: EXPERIMENTAL
Intervention: Hypertension (defined as known hypertension or use of antihypertensive medication)
Number of subjects: 1138
Study: 35062149

Group type: EXPERIMENTAL
Intervention: ADHERA CARING digital platform for emotional and self-management support
Number of subjects: 0
Study: 35062926

Group type: EXPERIMENTAL
Intervention: Fruit and Vegetable Prescription Program (FVPP) with high exposure (> 24 months)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Fruit and Vegetable Prescription Program (FVPP) with moderate exposure (12-24 months)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Fruit and Vegetable Prescription Program (FVPP) with no previous exposure
Number of subjects: 700
Study: 35062967

Group type: EXPERIMENTAL
Intervention: Higher baseline levels of moderate-intensity physical activity
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Higher baseline levels of vigorous-intensity physical activity
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Light-intensity physical activity
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Change in activity levels across the school year
Number of subjects: 762
Study: 35062987

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C supplementation (40 mg/kg)
Number of subjects: 30
Study: 35063042

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation including high-intensity interval training and resistance training, nutritional support, dietician consultation, medical optimization, duration: at least 4 weeks
Number of subjects: 8
Study: 35063223

Group type: EXPERIMENTAL
Intervention: Bioimpedance methods (MF-BIA, SF-BIA, BIS)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bioimpedance methods (BIS by Matthie)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bioimpedance methods (BIS by Moissl)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bioimpedance methods (all)
Number of subjects: 62

Group type: COMPARATOR
Intervention: DXA
Number of subjects: 62
Study: 35063222

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 639
Study: 35063229

Group type: EXPERIMENTAL
Intervention: Erythrocyte selenium
Number of subjects: 109

Group type: COMPARATOR
Intervention: Plasma selenium
Number of subjects: 109
Study: 35063276

Group type: EXPERIMENTAL
Intervention: Olaparib maintenance monotherapy (300 mg twice daily)
Number of subjects: 279
Study: 35063882

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus concurrent chemoradiotherapy
Number of subjects: 957

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy alone
Number of subjects: 957
Study: 35064012

Group type: EXPERIMENTAL
Intervention: Prehospital ECG, troponin T (TnT), and transthoracic echocardiography (TTE) acquired by paramedics.
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Prehospital ECG, TnT, and TTE.
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Prehospital diagnostic methods (ECG, TnT, TTE).
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: RWMA as a diagnostic method.
Number of subjects: 253
Study: 35064011

Group type: EXPERIMENTAL
Intervention: Dostarlimab 500 mg every 3 weeks for 4 cycles, then 1000 mg every 6 weeks until disease progression (cohort A1, dMMR/MSI-H)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Dostarlimab 500 mg every 3 weeks for 4 cycles, then 1000 mg every 6 weeks until disease progression (cohort A2, MMRp/MSS)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Dostarlimab (combined cohorts)
Number of subjects: 290
Study: 35064138

Group type: EXPERIMENTAL
Intervention: HiBalance intervention (10-week balance exercise program)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study: 35064249

Group type: EXPERIMENTAL
Intervention: Patients with anxiety (262 individuals, 7.0%)
Number of subjects: 3724

Group type: COMPARATOR
Intervention: Patients without anxiety (3462 individuals, 93.0%)
Number of subjects: 3724
Study: 35064449

Group type: EXPERIMENTAL
Intervention: Low Adaptation group (n=130; 57% of participants)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: High Adaptation group (n=85; 37% of participants)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Both groups (Low and High Adaptation)
Number of subjects: 224
Study: 35064550

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Empagliflozin 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 0
Study: 35065038

Group type: EXPERIMENTAL
Intervention: CENTER-TBI frailty index score (range 0-30, standardized value range 0-1)
Number of subjects: 2993

Group type: EXPERIMENTAL
Intervention: CENTER-TBI frailty index score for older adults (aged ≥65 years)
Number of subjects: 2993

Group type: EXPERIMENTAL
Intervention: TRACK-TBI frailty index score (n=1667)
Number of subjects: 2993
Study: 35065046

Group type: EXPERIMENTAL
Intervention: DOAC continued group
Number of subjects: 468

Group type: COMPARATOR
Intervention: DOAC withheld group
Number of subjects: 468
Study: 35065058

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cemiplimab 350 mg intravenously every 3 weeks for 2 cycles followed by surgical resection.
Number of subjects: 21
Study: 35065290

Group type: EXPERIMENTAL
Intervention: Very High Repetitive Negative Thinking (VH-RNT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High Repetitive Negative Thinking (H-RNT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Healthy Comparison Volunteers
Number of subjects: 150
Study: 35065599

Group type: EXPERIMENTAL
Intervention: Loading dose of 0.2 mg/kg of cisatracurium
Number of subjects: 10
Study: 35065656

Group type: EXPERIMENTAL
Intervention: Motivational ketogenic nutrition adherence program (6 weeks)
Number of subjects: 9
Study: 35065678

Group type: EXPERIMENTAL
Intervention: BBT-VR (immersive virtual reality version of the Box and Block Test)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BBT-VR
Number of subjects: 45

Group type: COMPARATOR
Intervention: BBT
Number of subjects: 45
Study: 35065785

Group type: EXPERIMENTAL
Intervention: arsa-cel (gene therapy)
Number of subjects: 29
Study: 35065801

Group type: EXPERIMENTAL
Intervention: Radial artery collateral function assessment using radial artery pressure signals during manual occlusion.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual radial artery occlusion (RAO) to determine collateral flow index (CFI).
Number of subjects: 0
Study: 35065941

Group type: EXPERIMENTAL
Intervention: Patients with mechanical symptoms
Number of subjects: 100

Group type: COMPARATOR
Intervention: Patients without mechanical symptoms
Number of subjects: 100
Study: 35065975

Group type: EXPERIMENTAL
Intervention: High prevalence neighborhoods (HPN)
Number of subjects: 1238

Group type: COMPARATOR
Intervention: Low prevalence neighborhoods (LPN)
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Migration to rural areas
Number of subjects: 1238
Study: 35066090

Group type: EXPERIMENTAL
Intervention: FVIII/PC
Number of subjects: 576
Study: 35066175

Group type: EXPERIMENTAL
Intervention: Flare-OA questionnaire
Number of subjects: 398
Study: 35066531

Group type: EXPERIMENTAL
Intervention: Dual-source photon-counting detector computed tomography (PCD-CT) with late enhancement (LE) scan using 100 mL contrast media.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dual-source photon-counting detector computed tomography (PCD-CT) with late enhancement (LE) scan.
Number of subjects: 30
Study: 35066633

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CAD) software on ultrasound
Number of subjects: 901
Study: 35066693

Group type: EXPERIMENTAL
Intervention: Crenolanib 100 mg BID with paclitaxel 80 mg/m² and ramucirumab
Number of subjects: 27
Study: 35066801

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) for 104 weeks
Number of subjects: 0
Study: 35067071

Group type: EXPERIMENTAL
Intervention: Nonprimary percutaneous coronary intervention in women
Number of subjects: 18567

Group type: EXPERIMENTAL
Intervention: Nonprimary percutaneous coronary intervention in men
Number of subjects: 18567
Study: 35067072

Group type: EXPERIMENTAL
Intervention: Intracoronary CD34+ cell therapy
Number of subjects: 20
Study: 35067230

Group type: EXPERIMENTAL
Intervention: Vigabatrin (single loading dose of 4500 mg via enteric tube within 48 h of PASE onset)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 12
Study: 35067596

Group type: EXPERIMENTAL
Intervention: Phone-delivered mindfulness training (MT) for 30 minutes weekly for 8 weeks
Number of subjects: 33
Study: 35067599

Group type: EXPERIMENTAL
Intervention: Coinfection with Neisseria gonorrhoeae
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Coinfection with Chlamydia trachomatis
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Coinfection with both Neisseria gonorrhoeae and Chlamydia trachomatis
Number of subjects: 865
Study: 35067602

Group type: EXPERIMENTAL
Intervention: Vestibular Ocular Motor Screening (VOMS)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Dizziness Handicap Inventory (DHI)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Functional Gait Analysis
Number of subjects: 110

Group type: COMPARATOR
Intervention: Modified Illinois Agility Task
Number of subjects: 110

Group type: COMPARATOR
Intervention: Revised High-Level Mobility Assessment Tool
Number of subjects: 110
Study: 35067645

Group type: EXPERIMENTAL
Intervention: Pilot intervention study (Pilot 1) with 49 participants
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Longitudinal observational study (Pilot 2) with 45 participants
Number of subjects: 94
Study: 35067748

Group type: EXPERIMENTAL
Intervention: Sonication cultures
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tissue cultures
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Aspiration cultures
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Change in antibiotic treatment
Number of subjects: 64
Study: 35067817

Group type: EXPERIMENTAL
Intervention: Non-ablative Er:YAG laser treatment (IncontiLase® procedure)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Single-session maintenance treatments every 6 months
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Non-ablative Er:YAG laser treatment
Number of subjects: 43
Study: 35067914

Group type: EXPERIMENTAL
Intervention: Steroid treatment, specific dosage and duration not available
Number of subjects: 0
Study: 35068788

Group type: EXPERIMENTAL
Intervention: Combination of autologous HSC and MSC infusion
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) administration
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Coculturing MSCs with HSCs
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Monoculture of HSCs and MSCs
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Coculture of HSCs and MSCs
Number of subjects: 5
Study: 35069171

Group type: EXPERIMENTAL
Intervention: 12-week TT + VR intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: 6-week TT + VR intervention
Number of subjects: 96
Study: 35070353

Group type: EXPERIMENTAL
Intervention: Hospital-led physical activity resumption programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Community-based physical activity resumption programme
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 35070367

Group type: EXPERIMENTAL
Intervention: Percutaneous microwave ablation
Number of subjects: 15
Study: 35070788

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 52
Study: 35070795

Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists (ERA)
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: PDE-5 inhibitors
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Prostacyclin analogues
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: sGC stimulator riociguat
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Overall management strategies
Number of subjects: 769
Study: 35070991

Group type: EXPERIMENTAL
Intervention: Citarinostat 360 mg once daily plus paclitaxel 80 mg/m²
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Citarinostat 480 mg once daily plus paclitaxel 80 mg/m²
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Citarinostat 180 mg once daily plus paclitaxel 80 mg/m²
Number of subjects: 20
Study: 35071653

Group type: EXPERIMENTAL
Intervention: Low-dose group (24 patients)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Medium-dose group (25 patients)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High-dose group (24 patients)
Number of subjects: 75
Study: 35072046

Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 263

Group type: COMPARATOR
Intervention: Non-Black participants
Number of subjects: 263
Study: 35072138

Group type: EXPERIMENTAL
Intervention: Sunscreens with MCE
Number of subjects: 19

Group type: COMPARATOR
Intervention: Reference formulas (control)
Number of subjects: 19
Study: 35072135

Group type: EXPERIMENTAL
Intervention: Chronic RASI therapy
Number of subjects: 3812

Group type: EXPERIMENTAL
Intervention: In-hospital RASI therapy
Number of subjects: 3812
Study: 35072168

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg maintenance weeks 0/4/16/28/40
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 20
Study: 35072628

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mild infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Severe infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 0
Study: 35072722

Group type: COMPARATOR
Intervention: Glucocorticoid injection
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 156
Study: 35072864

Group type: EXPERIMENTAL
Intervention: Vincristine and dactinomycin (regimen EE4A)
Number of subjects: 8
Study: 35073148

Group type: EXPERIMENTAL
Intervention: Trastuzumab, Pertuzumab, and Docetaxel
Number of subjects: 45
Study: 35073248

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35073571

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PCV13 vaccination
Number of subjects: 30
Study: 35073727

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab + ipilimumab
Number of subjects: 0
Study: 35073769

Group type: EXPERIMENTAL
Intervention: Hypothermically stored amniotic membrane (HSAM)
Number of subjects: 10
Study: 35073853

Group type: EXPERIMENTAL
Intervention: Microbiome signature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microbiome correlations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biosamples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COVID-19 antigen and antibody associations
Number of subjects: 0
Study: 35073864

Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection (CHMI) with Plasmodium falciparum sporozoites NF54 strain (Sanaria® PfSPZ Challenge)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection (CHMI)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Observational field-based studies in children
Number of subjects: 142
Study: 35073935

Group type: EXPERIMENTAL
Intervention: Longer maternal telomere length
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Higher paternal age
Number of subjects: 950
Study: 35073963

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) prescribed based on pattern differentiation in addition to conventional medication (ConM)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional medication (ConM) only
Number of subjects: 160
Study: 35073985

Group type: EXPERIMENTAL
Intervention: Wearable hydration monitor (Sixty device), worn at every dialysis session and nocturnally over a three-week period.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bioimpedance measurements using the Fresenius body composition monitor, performed on 4 occasions as a comparator.
Number of subjects: 20
Study: 35074000

Group type: EXPERIMENTAL
Intervention: Culturally adapted, social support-based diabetes group visit model
Number of subjects: 14
Study: 35074020

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (840 kcal/day) for weight loss and diabetes remission, 12-week duration, monitored weekly for weight and blood glucose.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adapted online protocol with self-measurement at home and mobile app for data entry.
Number of subjects: 0
Study: 35074072

Group type: EXPERIMENTAL
Intervention: Ibrutinib-rituximab induction (12 cycles; oral ibrutinib 560 mg daily and intravenous rituximab 375 mg/m2)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: R-HCVAD (four cycles)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Overall treatment approach (ibrutinib-rituximab followed by R-HCVAD)
Number of subjects: 131
Study: 35074459

Group type: EXPERIMENTAL
Intervention: Protein intake
Number of subjects: 287
Study: 35074532

Group type: EXPERIMENTAL
Intervention: Nonalcoholic fatty liver disease fibrosis score (NFS)
Number of subjects: 3207

Group type: EXPERIMENTAL
Intervention: Fibrosis-4 index (FIB-4)
Number of subjects: 3207

Group type: EXPERIMENTAL
Intervention: Enhanced Liver Fibrosis test (ELF)
Number of subjects: 3207

Group type: EXPERIMENTAL
Intervention: Liver stiffness by vibration-controlled transient elastography
Number of subjects: 3207
Study: 35074631

Group type: EXPERIMENTAL
Intervention: Doppler-based resistive index (RI)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Semi-quantitative evaluation of renal perfusion using color-Doppler (SQP)
Number of subjects: 118
Study: 35074651

Group type: EXPERIMENTAL
Intervention: Vemurafenib and cetuximab combined with FOLFIRI
Number of subjects: 21
Study: 35074812

Group type: EXPERIMENTAL
Intervention: Germline genetic variants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demographic and clinical data from the SCCR
Number of subjects: 0
Study: 35075288

Group type: EXPERIMENTAL
Intervention: Gene therapy by autologous CD34+ cells, details on dosage and duration not available.
Number of subjects: 0
Study: 35075289

Group type: EXPERIMENTAL
Intervention: Lentiviral gene therapy
Number of subjects: 8
Study: 35075361

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 12
Study: 35075363

Group type: EXPERIMENTAL
Intervention: Sambiloto extract
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 35075450

Group type: EXPERIMENTAL
Intervention: mRNA BNT162b2 vaccine (two doses)
Number of subjects: 404
Study: 35075526

Group type: EXPERIMENTAL
Intervention: Shared mental models (SMMs) of the current situation
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SMMs of team resources
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: VATSAT score
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Duration of surgery
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Amount of intra-operative bleeding
Number of subjects: 58
Study: 35076026

Group type: EXPERIMENTAL
Intervention: Ellipsoid zone (EZ) loss progression rate
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Outer nuclear layer (ONL) thinning
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Inner segment (IS) thinning
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Outer segment (OS) thinning
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Genotype-phenotype analysis
Number of subjects: 66